On August 13, 2026, a new publication regarding insulin glargine U100 appeared in The Lancet Diabetes & Endocrinology. The publication is titled "Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial."
The article describes an open-label, multicentre, treat-to-target, randomised phase 3b trial. The trial, known as COMBINE 4, compared once-weekly IcoSema against once-daily insulin glargine U100 in the context of type 2 diabetes management.
This entry reflects the publication of the trial in the named journal on the stated date. No specific findings, outcomes, or comparative results are detailed here beyond the trial's design and title as reported.
Readers interested in additional background on insulin glargine can consult the compound overview for further context.